SLP’s AI drug‑simulation engine faces a big buyout moment

The thesis

Simulations Plus (SLP) builds software that lets drug makers test medicines on a computer before they ever reach human trials, using AI and advanced modeling instead of guesswork.[8] In April 2026, the company grew quarterly revenue 8% to $24.3M, with high‑margin software making up 60% of sales and solid operating profits.[6][2] Then in June 2026, SLP agreed to be bought by Altaris for about $375M, or $18.50 per share in cash, a 26% premium to its 60‑day average price.[1][9] Altaris plans to merge SLP with its Chemical Computing Group unit, creating a bigger drug‑simulation platform. The near‑term story is now mainly about that deal closing as expected in Q4 2026.[1][6]

Everyone wishes they'd bought Nvidia early. Here's how to spot the next one.

The biggest winners of the last decade had one thing in common. Our data follows those exact moves — and turns them into 10 names to watch right now.

The big names in the AI, Space, Nuclear and Robotics race. The window to get in early is closing fast. Don't wait.

See the top 10 stocks now — free ›

💡 Why this matters

Most new medicines still take years and billions of dollars to develop, with a lot of failures along the way. Simulations Plus is part of the push to change that by letting pharma companies run "virtual" trials using AI and digital human models before spending huge sums in the real world.[8] That fits squarely into the AI and genomics wave: more data about how bodies work, and smarter software to predict what a drug will do. If this approach works at scale, it could make drug development faster, cheaper, and more tailored, which matters for anyone who cares about better treatments and healthcare costs.[3][5][8]

▲ Catalysts

+ Altaris all‑cash buyout at $18.50 per share, ~26% premium, targeted to close Q4 2026.[1][6][9]
+ Planned combination with Altaris’ Chemical Computing Group to build a larger drug‑simulation software platform after the deal closes.[1][5]
+ Q2 FY26 results: revenue up 8% to $24.3M, gross margin 66%, adjusted EPS $0.35, showing healthy underlying business.[6][2]
+ Collaboration with Lonza and U.S. FDA on complex oral drug modeling, boosting credibility with big industry players and regulators.[3][5]
+ Technical collaboration with NVIDIA to add GPU and AI power to SLP’s modeling engines, aimed at faster simulations.[5]

▼ Risks

! Deal risk: Altaris buyout still needs shareholder and regulatory approval; if it fails, the stock could drop back toward standalone value.[1][6]
! Growth risk: FY26 guidance calls for only about 0–4% revenue growth, showing the business is not in a fast‑growth phase.[2][6][7]
! Customer risk: slower software renewals from smaller biotechs and a sharp decline in clinical‑services revenue.[2][6]
! Competition: crowded pharma software space, plus any misstep integrating with Chemical Computing Group after the buyout.[1][5]

🎯 One thing to take away

If you look at SLP today, you’re mostly looking at a merger story, not a long‑term solo growth stock. The core business is solid: it sells specialized AI‑driven software that helps pharma companies test drugs virtually, and it’s still profitable with decent growth and high margins.[6][2][8] But management expects only low single‑digit revenue growth for FY26, and that’s likely one reason they agreed to sell.[2][6][7] Altaris is offering $18.50 in cash per share and plans to merge SLP with its Chemical Computing Group unit, aiming to build a bigger drug‑simulation platform.[1][5][9] For a retail investor, this is mainly about how confident you are that the all‑cash deal closes as planned and whether the premium already priced into the stock is worth the remaining risk.

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.

Thinking about SLP?

Our data likes 10 other stocks even more right now — under-the-radar names we believe have monster upside potential. Get the free list before the crowd catches on.

Show me the 10 stocks — free →

Free · no credit card · unsubscribe in one click

Not investment advice. We share research and analyses for educational purposes. Investing in stocks involves risk, including possible loss of capital. Always do your own research.